Clinical TrialJun 4, 2026, 07:01 AM
Ocular Therapeutix to Present OTX-TKI Clinical Data at Summit 2026
AI Summary
Ocular Therapeutix announced its participation in Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas. The company will present multiple updates on its investigational product candidate, OTX-TKI (AXPAXLI), for retinal diseases such as wet age-related macular degeneration (nAMD) and nonproliferative diabetic retinopathy (NPDR). Key presentations include efficacy and safety outcomes from the SOL-1 Phase 3 trial and an update on the HELIOS program, alongside fireside chats and a panel discussion featuring company leadership.
Key Highlights
- Ocular Therapeutix to participate in Clinical Trials at the Summit 2026 on June 12-13, 2026.
- Fireside Chat on OTX-TKI: Overview of Science with Wiley Chambers on June 12.
- Presentation on SOL-1 Phase 3 Superiority Trial efficacy outcomes with OTX-TKI in nAMD on June 13.
- Presentation on Safety and Tolerability Profile of OTX-TKI in nAMD on June 13.
- HELIOS Program Update on OTX-TKI in Nonproliferative Diabetic Retinopathy on June 13.
- Fireside Chat with Pravin U. Dugel on innovation, leadership, and patient impact on June 13.
- Panel discussion on bringing novel treatments to market, moderated by Pravin U. Dugel on June 13.
Price Impact
More from OCUL